Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Ireland and UK or involving organisations from these countries.

Total search results: 2029 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Iksuda Therapeutics–Celltrion: investment, 202106 financing round totalling $47m incl co-lead investor Celltrion 2021-06-07
Iksuda Therapeutics–Mirae Asset: investment, 202106 financing round totalling $47m incl co-lead investor Mirae Asset Capital 2021-06-07
Iksuda Therapeutics–SEVERAL: investment, 202106 financing round $47m co-led by Mirae Asset Capital + Celltrion 2021-06-07
ViveBiotech–Image Box: public relations, 202106 service existent by Image Box Communications 2021-06-04
Amyl Therapeutics–Huntsworth: public relations, 202106 service existent by Citigate Dewe Rogerson 2021-06-03
ImaginAb–Norgine: investment, 202106 financing round totalling $12.8m incl new + co-investor Norgine Ventures 2021-06-03
ImaginAb–SEVERAL: investment, 202106 financing round $12.8m co-led by existing investors Adage Capital + Cycad Group 2021-06-03
AstraZeneca–Celonis: management execution software, 202106 supply existent customer AstraZeneca 2021-06-02
GoSilico–Danaher: investment, 202106 acquisition of GoSilico GmbH by Cytiva 2021-06-02
GSK–Celonis: management execution software, 202106 supply existent customer GSK 2021-06-02
Transine Therapeutics–Huntsworth: public relations, 202106 service existent by Citigate Dewe Rogerson 2021-06-02
Transine Therapeutics–SEVERAL: investment, 202106 seed financing round £9.1m co-led by Takeda Ventures + Dementia Discovery Fund 2021-06-02
Transine Therapeutics–SV Health Investors: investment, 202106 seed financing round totalling £9.1m incl co-lead investor Dementai Discovery Fund 2021-06-02
Transine Therapeutics–Takeda: investment, 202106 seed financing round totalling £9.1m incl co-lead investor Takeda Ventures 2021-06-02
Macrophage Pharma–Optimum Strategic Communications: public relations, 202106 service existent by Optimum 2021-06-01
Univ Belfast–Agilent: grant, 202106– Thought Leader Award to Prof Chris Elliott at QUB IGFS for food safety analysis 2021-06-01
Univ Belfast–Agilent: LC system, 202106 supply 1290 Infinity II LC System as part of Thought Leader Award grant to QUB IGFS 2021-06-01
Univ Belfast–Agilent: mass spectrometer, 202106 supply 6546 LC-Q/TOF instrument as part of Thought Leader Award grant to QUB IGFS 2021-06-01
Univ Belfast–Agilent: mass spectrometer, 202106 supply 7850 ICP-MS instrument as part of Thought Leader Award grant to QUB IGFS 2021-06-01
Pulmocide–Adjuvant Capital: investment, 202105 financing round Series C totalling $92m incl new + co-investor Adjuvant Capital 2021-05-27
Pulmocide–Asahi Kasei: investment, 202105 financing round Series C totalling $92m incl new + co-investor Asahi Kasei Pharma 2021-05-27
Pulmocide–Consilium: public relations, 202105 service existent by Consilium Strategic Communications 2021-05-27
Pulmocide–F-Prime: investment, 202105 financing round Series C totalling $92m incl existing + co-investor F-Prime Capital 2021-05-27
Pulmocide–IP Group: investment, 202105 financing round Series C totalling $92m incl existing + co-investor IP Group plc 2021-05-27
Pulmocide–Jeito Capital: investment, 202105 financing round Series C totalling $92m incl new + lead investor Jeito Capital 2021-05-27
Pulmocide–JnJ: investment, 202105 financing round Series C totalling $92m incl existing + co-investor JnJ Innovation JJDC Inc 2021-05-27
Pulmocide–Longwood Fund: investment, 202105 financing round Series C totalling $92m incl existing + co-investor Longwood Fund 2021-05-27
Pulmocide–SEVERAL: investment, 202105 financing round Series C $92m led by new investor Jeito Capital 2021-05-27
Pulmocide–SR One: investment, 202105 financing round Series C totalling $92m incl existing + co-investor SR One 2021-05-27
Pulmocide–SV Health Investors: investment, 202105 financing round Series C totalling $92m incl existing + co-investor SV Health Investors 2021-05-27
Haya Therapeutics–Schroders: investment, 202105 seed financing round totalling CHF18m incl co-investor Schroder Adveq 2021-05-20
Haya Therapeutics–SEVERAL: investment, 202105 seed financing round CHF18m led by Broadview Ventures 2021-05-20
BMS–Exscientia: AI-based drug discovery, 202105– collab $50m upfront + $1.2b milestones + royalties discovery small molecules mutliple disease areas 2021-05-19
Immunodiagnostic Systems–PerkinElmer: investment, 202105– recommended all cash offer £110m by PerkinElmer ANNOUNCED 2021-05-17
Biocatalysts Ltd–BRAIN Biotech: investment, 202105 acquisition addit 16.7% for £3.9m bringing total to 82.2% with 2 put options excercised 2021-05-12
Nexcelom Bioscience–PerkinElmer: investment, 202105– acquisition $260m in cash from founders + Ampersand Capital Partners 2021-05-12
Athenex–Cooley: legal services, 202105 supply service Cooley (UK) acted as sole advisor to Athenex with regard to acquisition of Kuur Therapeutics 2021-05-04
Kuur Therapeutics–Athenex: investment, 202105 acquisition $70m upfront (mainly in shares) + $115m milestones by Athenex 2021-05-04
Kuur Therapeutics–HMB Legal Counsel: legal services, 202105 supply service HMB Legal legal advisor to Kuur with regard to acquisition by Athenex 2021-05-04
Kuur Therapeutics–SVB: financial services, 202105 supply service SVB Lerrink financial adivsor to Kuur with regard to acquisition by Athenex 2021-05-04
Oxford Nanopore–SEVERAL: investment, 202105 financing round £195m from new + existing investors 2021-05-04
Adcendo–Optimum Strategic Communications: public relations, 202104 service existent by Optimum 2021-04-29
Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe 2021-04-28
Kaia Health–Hot Cherry PR: public relations, 202104 service existent by Hot Cherry PR 2021-04-28
Kaia Health–SEVERAL: investment, 202104 financing round Series C $75m led by undisclosed growth equity fund 2021-04-28
Exscientia–BlackRock: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BlackRock 2021-04-27
Exscientia–BMS: investment, 202104 financing round Series D totalling $225m incl existing + co-investor BMS 2021-04-27
Exscientia–Casdin Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Casdin Capital 2021-04-27
Exscientia–Farallon Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Farallon Capital 2021-04-27
Exscientia–GT Healthcare Capital Partners: investment, 202104 financing round Series D totalling $225m incl co-investor GT Healthcare 2021-04-27
Exscientia–Hongkou: investment, 202104 financing round Series D totalling $225m incl co-investor Hongkou 2021-04-27
Exscientia–Laurion Capital: investment, 202104 financing round Series D totalling $225m incl co-investor Laurion Capital 2021-04-27
Exscientia–Marshall Wace: investment, 202104 financing round Series D totalling $225m incl co-investor Marshall Wace 2021-04-27
Exscientia–Nan Fung: investment, 202104 financing round Series D totalling $225m incl co-investor Pivotal BioVenture Partners 2021-04-27
Exscientia–Novo Group: investment, 202104 financing round Series D totalling $225m incl existing + co-investor Novo Holdings 2021-04-27
Exscientia–SEVERAL: investment, 202104 financing round Series D $225m led by SoftBank Vision Fund 2 2021-04-27
Exscientia–SoftBank: investment, 202104 financing round Series D totalling $225m incl lead investor SoftBank Vision Fund 2 2021-04-27
Exscientia–SoftBank: investment, 202104– equity commitment up to $300m by SoftBank than can be drawn at Exscientia’s discretion 2021-04-27
Exscientia–United Arab Emirates (govt): investment, 202104 financing round Series D totalling $225m incl co-investor Mubadala Investment Company 2021-04-27
Forbion–SEVERAL: investment, 202104 additional €175m + final closing at hard cap of €360m of Forbion Growth Opportunities Fund I 2021-04-20
Mestag Therapeutics–JnJ: investment, 202104 seed financing round totalling $11m incl Johnson & Johnson Innovation JJDC Inc 2021-04-20
Mestag Therapeutics–JW Communications: public relations, 202104 service existent by JW Communications 2021-04-20
Mestag Therapeutics–SEVERAL: investment, 202104 seed financing round $11m with SV Health Investors + JJDC 2021-04-20
Mestag Therapeutics–SV Health Investors: investment, 202104 seed financing round totalling $11m incl SV Health Investors 2021-04-20
Rinri Therapeutics–BioCity (GB): investment, 202104 financing round totalling £10m incl existing investor BioCity 2021-04-20
Rinri Therapeutics–Boehringer: investment, 202104 financing round totalling £10m incl existing investor BIVF 2021-04-20
Rinri Therapeutics–SEVERAL: investment, 202104 financing round £10m from existing investors + incl convertible loan from UK Future Fund 2021-04-20
Rinri Therapeutics–UCB: investment, 202104 financing round totalling £10m incl existing investor UCB Ventures 2021-04-20
Rinri Therapeutics–United Kingdom (govt): credit, 202104 financing totalling £10m incl convertible loan from UK Future Fund 2021-04-20
Sense Biodetection–Cambridge Innovation Capital: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor CIC 2021-04-20
Sense Biodetection–Earlybird: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Earlybird Health 2021-04-20
Sense Biodetection–Koch Industries: investment, 202104 financing round Series B totalling $50m incl new + lead investor Koch Disruptive Technologies 2021-04-20
Sense Biodetection–Mercia: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Mercia Asset Management 2021-04-20
Sense Biodetection–PERSON: investment, 202104 financing round Series B totalling $50m incl exisiting + co-investor Jonathan Milner 2021-04-20
Sense Biodetection–SEVERAL: investment, 202104 financing round Series B $50m led by Koch Disruptive Technologies 2021-04-20
Alchemab–RA Capital: investment, 202104 financing round Series B totalling £60m incl lead investor RA Capital Management 2021-04-15
Alchemab–SEVERAL: investment, 202104 financing round Series B £60m led by RA Capital Management 2021-04-15
ATMPS–Oribiotech: CAGT manufacturing technology, 202104– collab ww for integrated digital patform for CAGT developers using Hataali platform 2021-04-14
Camtech Diagnostics–Congenica: bioinformatics, 202104– distribution of Congenica’s platform in SG+MY+JP+KR 2021-04-13
Metrion Biosciences–Gresham House: investment, 202104 financing round totalling £2.7m incl £2.25m from lead investor Gresham House Ventures 2021-04-06
Metrion Biosciences–SEVERAL: investment, 202104 financing round £2.7m led by Gresham House Ventures with £2.25m 2021-04-06
Pyxis Oncology–SEVERAL: investment, 202103 financing round Series B $152m led by Arix Bioscience 2021-03-30
Gyroscope Therapeutics–Cambridge Innovation Capital: investment, 202103 financing round Series C totalling $148m incl co-investor CIC 2021-03-26
Gyroscope Therapeutics–Forbion: investment, 202103 financing round Series C totalling $148m incl lead investor Forbion Growth I 2021-03-26
Gyroscope Therapeutics–Fosun: investment, 202103 financing round Series C totalling $148m incl co-investor Fosun Pharma 2021-03-26
Gyroscope Therapeutics–OTHER: investment, 202103 financing round Series C totalling $148m incl co-investor undisclosed healthcare focused fund 2021-03-26
Gyroscope Therapeutics–SEVERAL: investment, 202103 financing round Series C $148m led by Forbion Growth I 2021-03-26
Gyroscope Therapeutics–Sofinnova: investment, 202103 financing round Series C totalling $148m incl co-investor Sofinnova Investments 2021-03-26
Gyroscope Therapeutics–Syncona: investment, 202103 financing round Series C totalling $148m incl existing + co-investor Syncona 2021-03-26
Gyroscope Therapeutics–T Rowe Price: investment, 202103 financing round Series C totalling $148m incl co-investor T Rowe Price Associates Inc 2021-03-26
Gyroscope Therapeutics–Tetragon Financial Group: investment, 202103 financing round Series C totalling $148m incl co-investor TFG 2021-03-26
Inbrain Neuroelectronics–SEVERAL: investment, 202103 financing round Series A €14.35m led by Asabys Partners incl follow-on from ICF VTII 2021-03-26
Dunad Therapeutics–Epidarex Capital: investment, 2020–202103 Dunad emerges from stealh with seed financing from Epidarex Capital 2021-03-23
Dunad Therapeutics–Huntsworth: public relations, 202103 service existent by Citigate Dewe Rogerson 2021-03-23
PhoreMost–SEVERAL: investment, 202103 financing round Series B £33m led by BGF 2021-03-23
Aura Biosciences–SEVERAL: investment, 202103 financing round $80m led by Matrix Capital Management + Surveyor Capital 2021-03-22
Dotmatics–Insightful Science: investment, 202103– €na (£500m approx) acquisition of Dotmatics Ltd by Insightful Science LLC ANNOUNCED 2021-03-22
Amphista Therapeutics–SEVERAL: investment, 202103 financing round Series B £38m ($53m) co-led by Forbion + Gilde Healthcare 2021-03-17
Alchemab–DCVC: investment, 2019 seed financing round incl investor Data Collective VC 2021-03-16
Alchemab–Instinctif Partners: public relations, 202103 service existent by Instinctif 2021-03-16
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21  next pagenext page



Advertisement

Picture EBD Group Connector Personal Networking in Life Sciences 650x80

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Hotspot for Startups 650x80px

» top